From 14 to 16 June, Diater was present at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Glasgow. The company reaffirmed its commitment to the advancement of immunotherapy based on purified allergens and the development of scientific tools at the service of healthcare professionals.
A key meeting for the international scientific community
EAACI 2025 brought together more than 7,000 professionals in the field of allergology and clinical immunology from over 100 countries. The programme included multiple symposia, plenary sessions and activities focusing on the latest innovations in immunotherapy, molecular diagnostics and continuing medical education strategies.
One of the highlights of this edition was the launch of NEXUS, EAACI's new educational platform, which brings together digital content on demand in different formats (video, podcast, article) and reinforces the organisation's commitment to sustainability and flexible access to knowledge.
A space designed to project Diater's scientific and corporate identity
The Diater stand at EAACI 2025 was conceived as a meeting point for professionals interested in innovation in immunotherapy and diagnostics. More than a traditional exhibition space, it offered a corporate experience focused on interaction, knowledge and the company's identity.
One of the most valued proposals was the boutique cafeteria, where more than 400 "molecular" coffees were served as part of an informative action. This initiative, together with access to the new professional website, participation in clinical quizzes and direct contact with the entire DIATER team, made it possible to publicise Diater's strategic lines in a close, rigorous and differentiated way.
International presence and professional collaboration
Participation in EAACI 2025 also made it possible to hold meetings with distributors, researchers and institutional representatives from multiple countries. These interactions reinforced the interest in molecular allergens as a tool for a more specific and personalised approach to allergic patients.
The exhibition model, focused on science and professional dialogue, was especially appreciated by attendees interested in evidence-based information aligned with current trends in immunotherapy.
Looking ahead
Diater continues to strengthen its international presence as a company committed to research, transparency and the generation of clinically relevant knowledge. Direct contact with the medical community at EAACI has identified new areas of scientific collaboration and technical dissemination.
Participating in EAACI 2025 has allowed us to actively listen to healthcare professionals, share our latest developments in purified allergens and continue to consolidate a vision of the future focused on precision immunotherapy
Pablo Mingote, International Product Manager de Diater.